The reliable detection of paraprotein in serum and urine is the primary purpose of electrophoretic procedures in clinical laboratories. Screening immunofixation electrophoresis (sIFE) employs a single application of antisera directed against heavy and light chains that facilitates the detection of paraproteins that migrate in the non-γ region or that are below the detection limit of protein electrophoresis. These paraproteins that are missed by routine electrophoresis occur in up to 27.3% of newly investigated and 13.6% of monitored patients. Small paraproteins missed by conventional electrophoretic techniques are clinically important in the diagnosis and monitoring of malignant plasma and B-cell disorders. The superior diagnostic performance of sIFE makes it suitable as the initial laboratory procedure to investigate paraproteins in complex serum and urine matrices.
Introduction
The reliable detection of monoclonal immunoglobulins (paraprotein) in serum and urine is the primary concern of clinicians when ordering electrophoresis. Screening immunofixation electrophoresis (sIFE) is a modified immunofixation (IFE) procedure that employs a single application of combined antisera directed against heavy and/or light chains to detect a paraprotein. The technical aspects and diagnostic performance of sIFE is dealt with in detail elsewhere [1, 2] . The clinical rationale behind detecting small paraproteins and the analytical characteristics of the available procedures will be briefly discussed to justify the recommendation that sIFE should be the initial laboratory procedure to investigate paraproteins in complex serum and urine matrices.
Clinical considerations
The presence, size and composition of paraproteins are of interest to clinicians in the diagnosis, risk stratification and monitoring of the monoclonal gammopathies and clinical laboratories have developed elaborate protocols and guidelines to satisfy these requirements [3] . The contribution of protein electrophoresis to the diagnosis of nephrotic syndrome, liver cirrhosis, acute inflammation and other conditions is marginal at best and will not be further considered as more appropriate investigations are available. The clonal plasma and B-cell disorders are a heterogeneous group that includes myeloma, plasmacytoma, lymphoma, chronic lymphocytic leukaemia, light chain amyloidosis, heavy chain disease and the premalignant monoclonal gammopathy of undetermined significance (MGUS) [4, 5] .
To estimate the positive predictive value when a paraprotein is detected in a clinical sample it is helpful to consider the prevalence of the respective conditions. In two well-conducted population-based series MGUS was detected in 3.2% of individuals older than 50 years and in 3.5% of individuals older than 40, respectively [1, 6] . The reported population prevalence of myeloma demonstrates geographic variability ranging from 0.020% in the UK (circa 2012), 0.026% in Australia (circa 2007) and 0.029% in the USA (circa 2012) [7] [8] [9] . This approximate 100:1 ratio in the population generally corresponds to the reported progression rate of MGUS to myeloma and related conditions. However, reports on the disease spectrum seen at healthcare institutions indicate that MGUS contributes between 51% and 54%, the myeloma group of diseases 25%-33% and light chain amyloidosis 1%-11% of the monoclonal gammopathy caseload [5, 10] . This 1.6-2: 1 ratio of MGUS to myeloma is in contrast to that suggested by the population prevalences and probably reflects the effect of targeted investigations based on clinical presentation on yield, as opposed to indiscriminate population based screening.
Multiple myeloma is consistently preceded by MGUS [11] and the risk factors for progression are the size and type of paraprotein, degree of plasma cell infiltration and serum free light chain levels [4, 5, 12] . The 20-year risk of progression with a paraprotein < 5 g/L is 14% while those with levels above 15 g/L nearly twice as likely to progress to myeloma or a related disorder. In patients with paraproteins that were detected by IFE only and therefore, deemed too small to quantitate, 3.2% progressed to plasma cell malignancy during a median follow-up of 3.9 years [13] . In the same series 30% of the small unquantifiable paraproteins were transient compared to the expected 0.4% of conventional MGUS cases. Despite the unquestionable relationship of MGUS progression risk with increased paraprotein levels, there is no evidence that this becomes negligible at very low paraprotein levels and that small paraproteins can be safely ignored. On the contrary there is evidence that suggests a significant proportion of these patients will progress and thus may benefit from clinical surveillance and care.
The current diagnostic criteria for multiple myeloma requires more than 10% clonal plasma cells in the bone marrow or a biopsy proven plasmacytoma and the presence of myeloma defining end organ damage as a consequence of plasma cell proliferation [14] . There is no mandatory requirement for the presence of a paraprotein or a minimum size with approximately 3% of multiple myeloma classified as non-secretory. It is also recognised that in light chain amyloidosis and Waldenstrom macroglobulinaemia the paraprotein can be so small that a sensitive detection method, such as IFE, is mandatory in the diagnostic workup [3, 5, 15] . The presence of a paraprotein is not sine qua non for the diagnosis of myeloma or myeloma related conditions, with the exception of MGUS. This further supports the view that there is no threshold below which small paraproteins can be dismissed as clinically insignificant.
The discovery that early intervention in high-risk asymptomatic patients with smouldering myeloma resulted in delayed progression to symptoms and to a survival benefit may have a profound impact on the future management of this disease spectrum [16] . Previously the standard paradigm of care was watchful observation until disease-defining symptoms develop, due to concerns about the toxicity of treatment regimens. With the availability of less toxic treatment modalities and emerging evidence of improved clinical outcomes it appears reasonable to speculate that the indications for disease modifying treatment may expand in the future.
There is a legitimate concern that we may unintentionally contribute to the Ulysses syndrome by inflicting unnecessary invasive investigations on MGUS patients diagnosed with small paraproteins [17] . The reported population prevalences detected by sIFE and conventional diagnostic approaches do not suggest that sIFE will result in a gross over-diagnosis of MGUS with very small paraproteins. The rate in individuals older than 40 years of 3.5% (95% CI 3.0%-4.1%) identified with sIFE was not significantly different from the 3.2% (95% CI 3.0%-3.5%) identified by conventional practice in individuals older than 50 years (χ 2 = 0.828, p = 0.36) [1, 6] . The difference remained statistically insignificant when only individuals above 50 years were considered (χ 2 = 3.55, p = 0.06). Even if the analytically more sensitive sIFE leads to a small increase in MGUS cases it also does not logically follow that these individuals will be investigated unnecessarily. The current clinical guidelines do not recommend invasive baseline bone marrow investigation or skeletal survey if the risk of progression is deemed to be low (paraprotein < 15 g/L and free light chains normal) unless myeloma defining end organ damage is present [12] .
Analytical and operational considerations
The sequential performance of serum and urine PE followed by reflexive addition of IFE dependant on the discovery of a suspected monoclonal immunoglobulin band, the clinical information supplied and the historical laboratory results represents the conventional laboratory approach to the investigation of paraproteins. This approach requires review by experienced laboratory scientists and it is often hampered by incomplete clinical information at the time of the investigation that results in inter-operator and inter-laboratory variability. A sequential testing cascade also has an obvious detrimental impact on turnaround times. The objective detection of a paraprotein by sIFE as the initial procedure, followed by quantification and characterisation of the paraprotein size by PE and composition by IFE where required is an alternative approach.
Of the available diagnostic techniques standard agarose or capillary PE has the worst ability to detect paraproteins with a detection limit of 0.5-1 g/L that depends on background staining of residual polyclonal immunoglobulin. This is further degraded when these bands migrate in non-γ regions [2, 3] . All newly detected bands with a localised migration on PE needs to be further investigated with IFE to confirm monoclonality. Conventional IFE with sequential application of antibody directed against heavy (G, A, M, D and E) and light (κ, λ) chains is the standard method for characterisation and confirmation of monoclonality. This technique is also capable of detecting smaller bands of 50-100 mg/L in serum and as low as 5 mg/L in urine that has resulted in this technique being specified to define the absence of a monoclonal band and to classify the therapeutic response categories [3, 16, 18] .
Screening IFE (sIFE) is a modified IFE that employs a single application of combined antisera (GAMκλ or κλ) to detect a paraprotein. This leverages the improved analytical sensitivity and specificity of immune typing techniques and approaches the efficiency of standard electrophoretic techniques [1, 2] . The principle is graphically illustrated in Figure 1 where samples were applied in an identical sequence on a standard PE and a sIFE gel. In the sera of newly investigated patients sIFE detected 22.1%±6.7% (95% CI) and 27.3%±6.7% of paraproteins that were not identified with PE [1, 2] . Approximately half of these paraproteins migrated in the β region and typed as IgA, IgM or as free light chains [2] that are recognised to confer a higher risk of progression than those with IgG subtypes [12] . Conventional PE missed 18.1%±2.8% of paraproteins in the sera of known patients who were followed up compared to 4.5%±1.5% that were missed by sIFE. The explanations for missed cases with sIFE include paraprotein levels below the detection limit of the assay, aberrant reactions with light chain antiserum or heavy chain disease if the screening antiserum is only directed against light chains [2, 19] . The response criteria for multiple myeloma differentiate between a complete response and a very good partial response based on the detection or otherwise of a paraprotein with IFE which in our experience was thus avoided in approximately 13.6% of monitored patients [2, 18] . The introduction of sIFE as initial analytical procedure resulted in reduced consumable costs and improved turn-around times because fewer reflexive IFE procedures were performed to confirm or refute the presence of small monoclonal bands in the sera of both new and known patients [2] . 
Summary
The reliable detection of small paraproteins is clinically important for the diagnosis of clonal plasma cell disorders as there is emerging evidence that a significant proportion of these patients will progress. Nearly half of paraproteins detected at healthcare institutions are associated with malignant plasma and B-cell conditions and the detection of small bands may be an important diagnostic clue. Due to its superior diagnostic performance sIFE should replace PE as the initial laboratory investigation of paraproteinaemia.
